tbuckley/cabot-search huggingface dataset:
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials: Table 1
Authors: D. Isenberg, J. Merrill, R. Hoffman, M. Linnik, M. Morgan-Cox, M. Veenhuizen, N. Iikuni, C. Dickson, M. Silk, D. Wallace, T. Dörner
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Tabalumab is a human IgG4 monoclonal antibody that binds and neutralizes membrane and soluble BAFF. <h3>Objectives</h3> Two trials, involving &gt;2000 patients (pts) with SLE, evaluated the efficacy and safety of subcutaneous tabalumab + standard of care (SoC) versus placebo (pbo) + SoC at 52 weeks (wks). <h3>Methods</h3> ANA-positive pts were enrolled with active, moderate-to-severe SLE (baseline SELENA-SLEDAI score ≥6). Pts with severe active renal or CNS disease were excluded. Pts received a loading dose (240 mg or pbo) at Wk 0, followed by 120 mg tabalumab every 2 wks (120 Q2W), 4 wks (120 Q4W), or pbo. Primary endpoint: proportion of pts achieving SLE Responder Index 5 (SRI-5) response at Wk 52. Key secondary endpoints: time to severe flare, corticosteroid sparing, and worst fatigue over last 24 hours (hrs). Subgroup analyses based on background SoC, complement, and anti-dsDNA were conducted. <h3>Results</h3> Baseline disease activity and clinical characteristics were balanced across groups in both trials. SRI-5 was not met in Trial 1, but was met in Trial 2 for the 120 Q2W dose (p=0.002; Table). Key secondary efficacy endpoints did not achieve statistical significance. Subgroup analysis showed that baseline antimalarial (AM) use did not reduce SRI-5 response rates. Reduction in anti-dsDNA was observed as well as increases in complement C3 and C4 and reduction in total B cells and immunoglobulins (Ig). The safety profile of the tabalumab and pbo groups was similar across both trials. <h3>Conclusions</h3> Tabalumab had biologic activity consistent with BAFF inhibition, as shown by anti-dsDNA, complement, B cell, and Ig changes. The primary endpoint was met in 1 of 2 trials for the 120 Q2W dose. <h3>Disclosure of Interest</h3> D. Isenberg Consultant for: Eli Lilly and Company, J. Merrill Grant/research support from: GlaxoSmithKline, Consultant for: Eli Lilly and Company, GlaxoSmithKline, Anthera Pharmaceuticals, EMD Serono, Speakers bureau: GlaxoSmithKline, R. Hoffman Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, M. Linnik Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, M. Morgan-Cox Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, M. Veenhuizen Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, N. Iikuni Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, C. Dickson Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, M. Silk Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, D. Wallace Consultant for: Eli Lilly and Company, T. Dörner Consultant for: Eli Lilly and Company, UCB, Roche/Chugai Pharmaceutical Co. Ltd., Sanofi
SP0252 The Case for Self-Management – 9 Years of Positive Patient Outcomes
Authors: G. O Leary
Journal: Annals of the Rheumatic Diseases (2015)

Arthritis Ireland pioneered the Stanford University developed Arthritis Self- Management Programme – known as <i>Living Well with Arthritis</i> in Ireland - back in 2006. This was in response to the needs of people with arthritis to help them deal with the complexities and life-transforming issues arising from living with arthritis. Since that time, we have delivered almost 250 courses to nearly 4,500 people living with all types of arthritis and rheumatic diseases through a network of over 80 trained course Leaders and 2 Master Trainers, most of whom are themselves living with arthritis. Research and evaluation are essential in providing the robust evidence that Arthritis Ireland9s courses are effective and that funding is being well spent. To this end we carried out a review amongst course participants from 2006 to 2010 with very positive outcomes. A 7% decrease in fatigue was recorded and sustained after 1 year. In relation to scores along the disability scale very positive results were shown with participants reporting 14% less disability around household chores and everyday tasks such as dressing and washing oneself. There was a 17% decrease, sustained at year 1, in participants9 arthritis interfering with social activities. Encouragingly, given the strong medical evidence that exercise is safe and effective in the fight against arthritis, participants reported a significant uptake in exercise behaviour such as stretching and strengthening work and aerobic exercise was sustained even at the 1 year stage. Some very encouraging results around the use of health care have shown that the <i>Living Well with Arthritis</i> Programme can reduce costs to the health system. In our study, patients reported a 25% reduction in visits to GPs, fewer emergency department visits, fewer visits to the hospital clinic and fewer overnight hospital stays. Furthermore, the programme has become a key tool for recruitment of highly engaged and committed volunteers for the organisation. The vast majority of volunteers involved in Arthritis Ireland support services are <i>Living Well with Arthritis</i> past participants, a noteworthy indicator of the powerful effect the course has had on their lives. <h3>Disclosure of Interest</h3> None declared
c-Myb acts in parallel and cooperatively with Cebp1 to regulate neutrophil maturation in zebrafish
Authors: Hao Jin, Zhibin Huang, Yali Chi, Mei Wu, Riyang Zhou, Lingfeng Zhao, Jin Xu, Fenghua Zhen, Yahui Lan, Li Li, Wenqing Zhang, Zilong Wen, Yiyue Zhang
Journal: Blood (2016)
Cerebellar pathology in schizophrenia: a controlled postmortem study
Authors: D R Weinberger, J E Kleinman, D J Luchins, L B Bigelow, R J Wyatt
Journal: American Journal of Psychiatry (1980)

In a morphometric study of the anterior cerebellar vermis of 47 brains in the Yakovlev collection, the area of the vermis of 5 of 12 brains of schizophrenic patients was smaller than that of any of 11 brains of control subjects without psychiatric or neurologic disease and 9 of 10 brains of control subjects with other psychiatric diagnoses (p less than .02). This finding confirms computerized tomography scan observations in live patients and supports the idea that some schizophrenic patients have structural abnormalities of the cerebellar vermis.
Influence of nondepressive psychiatric symptoms on whether patients tell a doctor about depression
Authors: K K Bucholz, S H Dinwiddie
Journal: American Journal of Psychiatry (1989)

The authors studied the other recent psychiatric symptoms of 218 subjects who reported having had depressive episodes within the past year to determine the influence of the nondepressive symptoms on whether the subjects discussed the depressive episodes with a doctor. Symptoms of panic and obsessive-compulsive disorders encouraged discussion of a depressive episode, but symptoms of drug abuse/dependence inhibited such discussion. The findings illustrate the bias in studying only patients who seek treatment, point to groups of persons who may need psychiatric help, and provide insight into the complex process of help seeking.
SP0114 Interactions of the Immune System and Endothelium in the Development of Arthritis
Authors: L. Stangenberg
Journal: Annals of the Rheumatic Diseases (2015)

Rheumatoid arthritis is an organ-specific autoimmune disease. Using the well-established K/BxN arthritis model, our group could show several years ago that particularities of the vasculature are responsible for this feature. That study highlighted the importance of vascular permeability in the development of arthritis by allowing immune complexes as well as immune effector cells to leave the circulation and enter the peri-articular space. Vasoactive amines, mast cells, neutophils and FcgRIII were identified as critical parts for development of early site-restricted permeability after injection of K/BxN arthritic serum. Now, our group found further evidence for the key role that the vasculature, in particular endothelial cells play in the development of arthritis. Starting with the long-known clinical observation of hemiplegia-induced sparing of joints we were able to model the phenomenon in the K/BxN serum-transfer system by unilateral denervation. The result is a near-complete abrogation of clinically detectable arthritis in denervated joints. This observation adds to the increasing body of data that suggest a crosstalk between the immune and nervous system; the exact anatomic correlate that governs the interaction remains to be found. Interestingly, however, our data demonstrate that the rapid and joint-localized vascular leak that typically accompanies and promotes serum-transferred arthritis was compromised in those denervated limbs. Attempts at rescuing the leak with histamine or serotonin that were successful in our previous work failed in the current study. This prominent defect was reflected in the transcriptome of endothelial cells: the expression of several genes impacting vascular leakage or transendothelial cell transmigration were altered in denervated limbs. These findings highlight a previously unappreciated pathway to dissect and eventually target in inflammatory arthritis. <h3>Disclosure of Interest</h3> None declared
When I use a word: Sometimes, never
Authors: Jeff Aronson
Journal: BMJ (2006)

If something always happened, what percentage frequency would you assign to that event? Presumably 100%. And if something never happened? Presumably 0%. Well, not everyone shares that opinion. By “always” some mean as infrequently as 91% of the time, and “never” can mean as often as 2% of the time. The combined results of seven studies of what people mean when they use words such as always, commonly, often, frequently, occasionally, sometimes, seldom, rarely, and never are summarised in the table (for references see Drug Safety 2005;28: 851-70 [PubMed]). For comparison, I have also included definitions from the Oxford English Dictionary.



Table 1

Interpretations of words used to indicate frequencies





Look, for example, at “occasionally,” “infrequently,” and “seldom”; according to the dictionary they all mean roughly the same thing, but the frequencies that people think these words represent do not overlap at all. Perhaps the lexicographers should reconsider some of their definitions—although surely not “never”—nohow. And perhaps when we use words like this we should remember what the German conductor Hans Richter supposedly once said: “Up with your damned nonsense will I put twice, or perhaps once, but sometimes always, by God, never.”
An Induced Adaptation in a Transplantable Tumor of Mice
Authors: Barrett, Morris K., Deringer, Margaret K.
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article An Induced Adaptation in a Transplantable Tumor of Mice Get access Morris K. Barrett, M. D., Morris K. Barrett, M. D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret K. Deringer, Ph. D. Margaret K. Deringer, Ph. D. National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md.2 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 1, August 1950, Pages 51–59, https://doi.org/10.1093/jnci/11.1.51 Published: 01 August 1950 Article history Received: 28 March 1950 Published: 01 August 1950
Decreased Hemolysis of Red Cells Washed with Plasma-Lyte As Compared with 0.9% Sodium Chloride
Authors: Scott A. Kirkley, Kelly F Henrichs, Amy P. Schmidt, Majed A. Refaai, Richard P. Phipps, Sherry L Spinelli, Debra Masel, Jill M Cholette, Anthony Pietropaoli, Joanna M. Heal, Neil Blumberg
Journal: Blood (2015)
Immunotherapy for Melanoma
Authors: M S Mitchell
Journal: JAMA (1973)

Melanoma is one of the first tumors for which several types of immunotherapy have been applied extensively. It is becoming clear that although only a minority of patients respond to immunotherapy, those who do have a major clinical response experience an improvement in survival. Melanoma vaccines (active specific immunotherapy) have elicited clinical remissions in advanced disease, in some instances for years. They may have extended survival in resected stage II or III disease, although the results of controlled, randomized trials in these stages are still pending. Perhaps their major advantage is their nearly total lack of significant systemic toxicity. Gene-modified whole-cell vaccines, newer constructs involving cell membranes on synthetic beads, and purified immunogenic peptides are interesting second-generation vaccines. Cytokines such as interferon-alpha and interleukin-2 also have had a beneficial effect in approximately 20% of patients with advanced disease, with a suggestion of higher rates of response when interferon is combined with a vaccine. A randomized, controlled Intergroup study has shown that interferon-alpha at 10 million U/m2/d three times weekly for 2 y is superior to observation alone in prolonging relapse-free and overall survival in resected stage III patients. Other such trials are necessary to prove the usefulness of immunotherapy in melanoma, but its promise as a new approach to a difficult disease is already evident.
Case 3-1965
Authors: George F. Cahill, Richard B. Cohen
Journal: New England Journal of Medicine (1965)

Presentation of Case First admission. A fifty-eight-year-old automobile mechanic entered the hospital for splenectomy.Two years previously he was seen in the Medical Clinic because of a sensation of fullness in the left upper quadrant of the abdomen, and enlargement of the spleen was found. The hemoglobin was 12 gm. per 100 ml.; the white-cell count was 57,000, with 29 per cent neutrophils, 28 per cent band forms, 8 per cent myelocytes, 9 per cent late myelocytes, 9 per cent metamyelocytes, 2 per cent eosinophilic myelocytes, 1 per cent eosinophils, 2 per cent monocytes and 12 per cent basophils. The . . .
PWE-394 Are we misdiagnosing foreign body reaction to biologic implants as mesh-related infection?
Authors: S Zeidan, D Cruttenden-Wood, D Tarver, A Clarke, M Ahmad
Journal: Gut (2015)

<h3>Introduction</h3> Concern regarding mesh erosion has led to the increased use of biological implants in laparoscopic ventral rectopexy (LVR). There is a growing recognition that biological implants are not inert and their introduction into the body triggers a sequence of events leading to the formation of foreign body giant cells at the tissue/implant interface. This could lead to systemic inflammatory response syndrome (SIRS) that mimics mesh-related infection. <h3>Method</h3> The records of 4 patients readmitted after LVR were assessed retrospectively. A radiologist with an interest in pelvic floor surgery reviewed their CT scans. <h3>Results</h3> We performed 27 LVRs from October 2013–2014 using Biodesign<b><sup>®</sup></b>biological implant and 19 using synthetic mesh. 4 patients (15%) from the biologic cohort were re-admitted with pain and pyrexia and a pelvic abscess was suspected. CRP was raised in 4 (mean 276 at readmission and 99 at discharge) but in only one was the WCC elevated. All 4 received antibiotics and 2 patients had percutaneous drainage of sterile collections while the other two had no intervention. Those treated with drainage had a longer hospital stay and a delayed recovery compared with the observation only group. All made a complete recovery and none had either symptoms of their original prolapse or dysfunctional defecation. None of the patients in the synthetic mesh group were readmitted. <h3>Conclusion</h3> SIRS is a natural reaction to the implantation of non-inert foreign material as evidenced by elevated inflammatory mediators in the absence of a neutrophilia. This small study would suggest that the drainage of such 9collections9 following insertion of biological meshes is not only unnecessary but may run the risk of introducing sepsis into a sterile environment. The routine use of intravenous antibiotics might be unnecessary and a watchful waiting approach should be considered. <h3>Disclosure of interest</h3> None Declared.
Out-of-Hospital Cardiac Arrest
Authors: David J. Wilber, Hasan Garan, Dianne Finkelstein, Elizabeth Kelly, John Newell, Brian McGovern, Jeremy N. Ruskin
Journal: New England Journal of Medicine (1988)

We examined the role of electrophysiologic testing in the prediction of long-term outcome in 166 survivors of out-of-hospital cardiac arrest not associated with acute myocardial infarction. Ventricular arrhythmias were inducible in 131 patients (79 percent) at base line and were suppressed by antiarrhythmic drugs or surgery (or both) in 91 of 127 (72 percent). During a median follow-up period of 21 months, cardiac arrest recurred in 29 patients: 11(12 percent) of the 91 in whom inducible arrhythmias had been suppressed (including 5 patients in whom treatment had been discontinued), 12 (33 percent) of the 36 in whom inducible arrhythmias persisted, and 6 (17 percent) of the 35 in whom arrhythmias could not be induced at the initial electrophysiologic study. Cox survival analysis identified the following three variables as significant independent predictors of recurrent cardiac arrest: persistence of inducible ventricular arrhythmias (relative risk, 3.97 [95 percent confidence interval, 1.80 to 8.75], P = 0.0006), a left ventricular ejection fraction of 30 percent or less (relative risk, 2.60 [1.21 to 5.53], P = 0.0138), and the absence of cardiac surgery (relative risk, 4.20 [0.99 to 17.77], P = 0.0512). We conclude that electrophysiologic testing is useful in quantifying the subsequent risk of cardiac arrest among survivors of out-of-hospital cardiac arrest. (N Engl J Med 1988;318:19–24.)
Bariatric Surgery for Patients With Early-Onset vs Late-Onset Type 2 Diabetes
Authors: Lwin Aung, Wei-Jei Lee, Shu Chun Chen, Kong-Han Ser, Chun-Chi Wu, Keong Chong, Yi-Chih Lee, Jung-Chien Chen
Journal: JAMA Surgery (2016)

The prevalence of early-onset type 2 diabetes mellitus (T2DM), which responds poorly to medical treatment, is increasing. Bariatric surgery has been well recognized for its effectiveness in the remission of T2DM, but its effectiveness and durability in the remission of early-onset T2DM has not yet been explored.To compare the short- and long-term outcomes of bariatric surgery with a specific focus on the rate of remission of T2DM in patients with early-onset (age <40 years) and late-onset (age ≥40 years) T2DM.In this cohort study, 558 Taiwanese patients (339 with early-onset T2DM and 219 with late-onset T2DM) with a body mass index (calculated as weight in kilograms divided by height in meters squared) above 25 underwent bariatric surgery to ameliorate T2DM between January 1, 2007, and December 31, 2013. Patients were followed up for at least 1 year. Preoperative, perioperative, and postoperative clinical and laboratory data were prospectively collected and compared between the 2 groups.Rate of remission of T2DM (hemoglobin A1C <6.0% without antiglycemic medication) was the primary outcome measure.Of the 558 patients (345 women) in the study, mean (SD) ages were 33.5 (7.5) for those with early-onset T2DM and 50.6 (6.5) with late onset T2DM. Those with early-onset T2DM had higher mean (SD) preoperative BMI and hemoglobin A1C values (39.4 [8.5] and 8.7% [3.8%] of total hemoglobin [to convert hemoglobin to a proportion of total hemoglobin, multiply by 0.01], respectively) than did patients with late-onset T2DM (36.7 [7.5] and 8.2% [1.6%], respectively). Distribution of surgical procedures and major complications were similar between the 2 groups. At 1 year, patients with early-onset T2DM achieved greater weight loss than those with late-onset T2DM, although the difference was not statistically significant. A higher rate of complete remission of T2DM was observed in patients with early-onset T2DM than in those with late-onset disease (193 [56.9%] vs 110 [50.2%]; P = .02). At 5 years, patients with early-onset T2DM still maintained a higher rate of weight loss (mean [SD], 30.4% [11.8%] vs 21.6% [11.7%]; P = .002) and higher rate of remission (47 of 72 [65.3%] vs 26 of 48 [54.2%]; P = .04) than did those with late-onset disease. Age at bariatric surgery, duration of T2DM, and preoperative C-peptide level were independent predictors of remission. The remission rate was directly related to extent of weight loss. Multivariate analysis confirmed the higher rate of remission in the group with early-onset T2DM.This article describes the largest long-term study examining bariatric surgery for patients with early-onset T2DM. Bariatric surgery may achieve better and more long-lasting glycemic control in select patients with early-onset T2DM than in those with late-onset T2DM.
Concentrative Uptake of Azaserine by Neoplastic Plasma Cells and Lymphocytes&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Ellen Kann Pine
Journal: JNCI Journal of the National Cancer Institute (1958)

Five ascites tumor strains were investigated for their ability to concentrate azaserine intracellularly in vitro. The azaserine-sensitive 70429/S plasma-cell tumor accumulated azaserine to intracellular concentrations as high as 30 times the external concentration. The 2 azaserine-resistant sublines, 70429/AZ-R-1 and 70429/AZ-R-5, concentrated the drug less efficiently than the sensitive parent strain at extracellular concentrations below 10 µg. per ml. At higher concentrations there was no correlation between drug sensitivity and drug uptake. The spontaneously resistant 6C3HED lymphosarcoma accumulated azaserine least efficiently: At all concentrations tested, azaserine uptake was less than that of the plasma-cell tumors. The rate and extent of azaserine uptake was inhibited by 2,4-dinitrophenol, sodium azide, and p-chloromercuribenzoic acid, which also reversed previous drug uptake by 50 percent or more. Many amino acids inhibit azaserine accumulation and displace it from its intracellular site; both D- and L-isomers are active. A free α-amino and carboxyl group appear essential for blocking activity.
Absence of Effect of Urethane on the Latent Period of Tumors Induced with Subcutaneous Injections of the Agent of Chicken Tumor I
Authors: Bryan, W. Ray, Riley, Vernon T., Calnan, Dorothy
Journal: JNCI Journal of the National Cancer Institute (1947)

Journal Article Absence of Effect of Urethane on the Latent Period of Tumors Induced with Subcutaneous Injections of the Agent of Chicken Tumor I Get access W. Ray Bryan, W. Ray Bryan principal biologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Vernon T. Riley, Vernon T. Riley assistant biologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Calnan Dorothy Calnan junior bacteriologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 4, February 1947, Pages 203–206, https://doi.org/10.1093/jnci/7.4.203 Published: 01 February 1947 Article history Received: 08 November 1946 Published: 01 February 1947